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Abstract
Background Context: Disc degeneration is the leading cause of low back pain and is often characterized by a
loss of disc height, resulting from cleavage of chondroitin sulfate proteoglycans (CSPGs) present in the nucleus
pulposus. Intact CSPGs are critical to water retention and maintenance of the nucleus osmotic pressure. Decellularization of healthy nucleus pulposus tissue has the potential to serve as an ideal matrix for tissue engineering of the disc because of the presence of native disc proteins and CSPGs. Injectable in situ gelling matrices
are the most viable therapeutic option to prevent damage to the anulus fibrosus and future disc degeneration.
Purpose: The purpose of this research was to create a gentle decellularization method for use on healthy nucleus
pulposus tissue explants and to develop an injectable formulation of this matrix to enable therapeutic use without substantial tissue disruption.
Study Design: Porcine nuclei pulposi were isolated, decellularized, and solubilized. Samples were assessed to
determine the degree of cell removal, matrix maintenance, gelation ability, cytotoxic residuals, and native cell
viability.
Methods: Nuclei pulposi were decellularized using serial detergent, buffer, and enzyme treatments. Decellularized nuclei pulposi were solubilized, neutralized, and buffered. The efficacy of decellularization was assessed
by quantifying DNA removal and matrix preservation. An elution study was performed to confirm removal of
cytotoxic residuals. Gelation kinetics and injectability were quantified. Long-term in vitro experiments were
performed with nucleus pulposus cells to ensure cell viability and native matrix production within the injectable decellularized nucleus pulposus matrices.
Results: This work resulted in the creation of a robust acellular matrix (>96% DNA removal) with highly preserved sulfated glycosaminoglycans (>47%), and collagen content and microstructure similar to native nucleus
pulposus, indicating preservation of disc components. Furthermore, it was possible to create an injectable formulation that gelled in situ within 45 minutes and formed fibrillar collagen with similar diameters to native
nucleus pulposus. The processing did not result in any remaining cytotoxic residuals. Solubilized decellularized nucleus pulposus samples seeded with nucleus pulposus cells maintained robust viability (>89%) up to 21
days of culture in vitro, with morphology similar to native nucleus pulposus cells, and exhibited significantly
enhanced sulfated glycosaminoglycans production over 21 days.
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Conclusions: A gentle decellularization of porcine nucleus pulposus followed by solubilization enabled the creation of an injectable tissue-specific matrix that is well tolerated in vitro by nucleus pulposus cells. These matrices have the potential to be used as a minimally invasive nucleus pulposus therapeutic to restore disc height.
Keywords: Decellularized matrix, Disc degeneration, Injectable scaffold, Intervertebral disc, Nucleus pulposus,
Tissue engineering

Introduction
Low back pain will affect 70% to 80% of the population
at some point in their lifetime, and disc degeneration is
the leading cause of low back pain [1]. Disc degeneration is characterized by a loss of intervertebral disc (IVD)
height, reduced water content, end plate thickening, and
annular fissures [2–7]. Breakdown of the nucleus pulposus, a gelatinous matrix rich in collagen type II and chondroitin sulfate proteoglycans (CSPGs) [8,9], has been
implicated in disc degeneration [10]. The CSPGs have
sulfated glycosaminoglycan (sGAG) side chains that attract water, enabling the nucleus to withstand substantial
compressive loads and prevent nerve ingrowth [8,9,11].
Cleavage of the CSPGs and consequent loss of sGAG side
chains have been implicated in disease progression by
resulting in the loss of the ability of the nucleus to hold
water and therefore bear compressive loads [10]. The
loss of CSPGs may additionally enable innervation of the
disc and subsequent pain [11,12]. Discogenic pain is one
source of low back pain that is thought to arise from increased nociceptive fiber innervation in the IVD [13,14].
A variety of approaches are currently being investigated to repair the nucleus pulposus and prevent low
back pain from occurring. Tissue engineering approaches
often combine growth factors and cells to attempt to repair the nucleus pulposus; however, in the harsh catabolic environment of the degenerating disc, growth factors and cells cannot survive [15–20]. The addition of a
biomaterial carrier has the potential to increase cell viability and enable long-term growth factor delivery. Various synthetic and natural materials are currently being investigated for nucleus pulposus tissue engineering
[21–26]. However, synthetic materials, such as chemically modified hyaluronan, can have toxic byproducts or
result in a foreign body response [27–29].
An ideal solution for tissue engineering of the nucleus
pulposus would (1) mimic the native disc composition
and consist of a proteoglycan rich matrix to restore the
hydrostatic compressive resistance of the disc, (2) serve
as a cell carrier, (3) prevent innervation into the nucleus,
and (4) be deliverable via injection and in situ gelation.
Decellularized nucleus pulposus tissue has the potential
to be this ideal scaffold because it is composed of native
disc proteins and proteoglycans with similar structure
to native disc. In addition, a decellularized scaffold has
the potential to be developed into an injectable formulation that gels in situ.
Tissue-derived biomaterials can offer unique advantages over synthetic materials such as limited foreign
body response, native cell response, and integration into

surrounding tissue using endogenous enzymes [30–33].
However, to minimize immune rejection of the tissue and
to prevent the need for systemic immunosuppression, it
is essential to remove cells and antigens. Decellularization of tissue is a practice that has been used for decades
to create naturally derived scaffolds. Removal of cells and
antigens is essential to preventing an immune response;
however, decellularization must also maintain the composition and structure of the native tissue [33–36]. Decellularization techniques have been optimized for the
heart [37], lung [38], nerve [39], skin [40], brain [41],
and spinal cord [42], among other tissues, and can involve physical, chemical, and biological methods to lyse
cells, and subsequently remove cellular debris. Our laboratory has previously developed gentle decellularization
techniques for nerve tissue to preserve essential proteins,
proteoglycans, and microstructure [39,43], which would
be ideal for the delicate nucleus pulposus. To date, some
research has been performed to create decellularization
protocols for the nucleus pulposus [44–47], anulus fibrosus [48,49], and the intact IVD [50]. These matrices
have shown promise as viable scaffolds for IVD cells as
well as drivers of stem cell fate [44–50], although they
are not injectable or in situ gelling.
After a tissue has been decellularized, it is possible to
turn the tissue into an injectable in situ gelling biomaterial [37,51], which would enable an easier therapeutic
delivery with minimally invasive surgery. For IVD, an injectable in situ gelling material would support delivery
through a fine gauge needle with no disruption of the anulus fibrosus, while also enabling formation of a gel capable of supplementing load bearing of the nucleus pulposus. Works by Freytes et al. and Singelyn et al. document
the early processes to solubilize decellularized urinary
bladder matrix and heart tissue, enabling in situ gelation by using pepsin in hydrochloric acid [37,51]. Kwon et
al. used pepsin in acetic acid to solubilize cartilage [52].
Others have used modifications of these protocols to solubilize a variety of tissues, including brain [41], liver [53],
and tendon [54]. However, these protocols have not yet
been adapted to create injectable in situ gelling hydrogels from decellularized nucleus pulposus or IVD tissue.
The purpose of this research was to create a gentle
nerve decellularization method for use on the nucleus
pulposus tissue of the IVD, thereby creating a tissue-specific acellular matrix with increased maintenance of proteoglycans and sGAGs with the potential to prevent nerve
ingrowth and drive stem cell fate. In addition, we also
wanted to create an injectable formulation of this matrix
to enable therapeutic use without substantial disruption
of the anulus fibrosus.
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Fig. 1. Macroscopic image of lumbar spine segment after cleaning (Left) and dissection (Right).

Materials and methods
Nucleus pulposus harvest and processing
Whole spines were dissected en bloc from YorkshireLandrace porcine weighing 40 to 50 kg (Fig. 1). Excess
tissue was removed and spines were disarticulated into
cervical, thoracic, and lumbar segments. Spine segments
were stored at −80°C until use. Spine segments were
then thawed for 24 hours, and the nuclei pulposi were
isolated from the cervical, thoracic, and lumbar sections
of the spine using careful dissection, and stored for up to
1 hour in sterile 1× phosphate buffered saline (PBS) until use (Fig. 2A, B, and C).
The nuclei pulposi were decellularized using a gentle technique adapted from Hudson et al. previously developed in our laboratory. All samples were processed in
15 mL tubes in an orbital shaker at 15 rpm. The samples
were immersed in water for 7 hours, followed by 100
mM sodium and 50 mM phosphate buffer for 10 hours,
SB-10 detergent for 4 hours, 100 mM sodium and 50 mM
phosphate buffer for 15 minutes, Triton X-200/SB-16 for
3 hours, 100 mM sodium and 50 mM phosphate buffer

for 3 × 15 minutes, SB-10 detergent for 1.75 hours, 100
mM sodium and 50 mM phosphate buffer for 15 minutes, Triton X-200/SB-16 for 3 hours, 100 mM sodium
and 50 mM phosphate buffer for 3 × 15 minutes, and followed by DNase/RNase solution (75 U/mL/100μg/mL) for
34 hours. The decellularized nuclei pulposi (dNPs) were
then washed in 50 mM sodium and 10 mM phosphate buffer for 3 × 90 min. Macroscopic images of nuclei pulposi
before and after decellularization are illustrated in Fig. 2.
DNA removal and sGAG maintenance
DNA removal and sGAG maintenance were determined
using quantitative assays. Fresh nucleus pulposus (NP)
control and dNP samples were fixed in 4% paraformaldehyde (PFA) for 30 minutes and washed 3 × 15 minutes
in 1× PBS. Of each sample, 50 mg wet weight was cut and
digested in papain (4762, Sigma, St Louis, MO, USA) at
65°C for 18 hours. After digestion, DNA was analyzed using a Quant-IT PicoGreen assay (P7589, Thermo Fisher,
Waltham, MA, USA). The sGAG content was quantified
using a Blyscan assay (Biocolor, Carrickfergus, Ireland).
A total of six dNPs were quantified from the cervical,

Fig. 2. Macroscopic images of nuclei pulposi from the cervical, thoracic, and lumbar spine segments, respectively, before (A, B, C) and after (D, E, F) decellularization.
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thoracic, and lumbar segments of three distinct spines
and compared with matched fresh NP controls.
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Creation of an injectable dNP matrix

The collagen content of fresh NP control and dNP samples
was assessed using both soluble and insoluble collagen
assays. Fifty milligrams of fresh NPs and dNPs were digested in 1 mg/mL pepsin (P7012, Sigma) in 0.5M acetic
acid at 4°C for a minimum of 18 hours on a shaker plate.
After digestion, the soluble collagen assay was executed
followed by the insoluble assay using standard assay kits
(CLRS1000, CLRS2000, Biocolor). The collagen content
was normalized to wet weight. A total of six dNPs were
quantified from three distinct spines and compared with
six fresh NP controls.

In preparation for solubilization, dNPs were washed three
times in ddH2O and then lyophilized for 72 hours. After lyophilization, dNPs were cut in small pieces and pooled for
digestion (Fig. 5B). Chopped dNPs were suspended at 5 mg
to 20 mg/mL in 1 mg/mL pepsin in either 3% acetic acid
or 0.01 M hydrochloric acid with or without homogenization for 3 × 30 seconds. dNPs were then placed on a stir
plate at room temperature for 32 to 64 hours to facilitate
digestion. After 32 to 64 hours, each sample was neutralized using either 0.1M or 1Msodium hydroxide and buffered with 10% of 10× sterile PBS. The ability to thermally
gel was tested by pipetting 10 to 30 μL of solubilized dNPs
onto paraffin and incubating for 45 minutes at 37°C. Solubilized dNPs were stored at 4°C for up to 7 days until use.

Cell removal and maintenance of CSPGs

Gelation kinetics

Cell removal and maintenance of CSPGs after decellularization were qualitatively assessed using fluorescence
staining and confocal imaging. Decellularized and fresh
NP samples were fixed in 4% PFA for 30 minutes, washed
3 × 15 minutes in 1× PBS, and permeablized with 4%
goat serum and 0.5% Triton X-100 in 1× PBS. Following permeabilization, dNP samples were stained overnight with a primary antibody to CSPGs (C8035, 1:200,
Sigma) in blocking buffer containing 0.3% Triton X-100
(93443, Sigma) and 3% goat serum (G9023, Sigma) in
1× PBS. An Alexa Fluor 568 secondary antibody (A11031,
1:500, Thermo Fisher) was used to fluorescently label the
CSPG primary. All samples were then counterstained with
DAPI (D1306, Thermo Fisher) for 5 minutes and washed
3 × 5 minutes in 1× PBS. A Zeiss LSM 710 confocal microscope (Zeiss Microimaging Inc., Jena, Germany) was
used to take z-stacks through each NP sample. Maximum
intensity projections were created through z-thickness
matched samples to enable semi-quantitative analysis.

Thermal gelation of collagen occurs through fibrillar formation and crosslinking. As this process occurs, proteins
aggregate and form cross-links and the absorbance of
405 nm light increases. This phenomenon can be used
to determine gelation kinetics by examining the temporal increase and plateau in absorbance as gelation progresses to completion. To assess gelation kinetics, 50 μL
of chilled pre-gel solubilized dNP was placed into a 96well plate and absorbance was measured at 405 nm 37°C
using the Synergy HT Plate Reader (BioTek, Winooski,
VT, USA). Four batches of injectable dNPs were tested in
duplicate. Absorbance readings were recorded every 2
minutes over a total of 60 minutes. Type I collagen gels
were used as a positive control, and a solution of 3% acetic acid neutralized with 5 M sodium hydroxide and buffered with 10% 10× PBS was used as a negative control.
Data were normalized to the initial readings using Equation (1), where A is the absorbance, A0 describes the initial absorbance, and Amax is the maximum absorbance.

Collagen content

Assessment of cytotoxic residuals
Decellularized NP samples were eluted for 72 hours at
37°C in 10 mL of medium containing 89% DMEM:F12
(D8437, Sigma), 10% fetal bovine serum (16000044,
Life Technologies, Carlsbad, CA, USA), and 1% penicillin-streptomycin (51606, EMD Millipore, Billerica, MA,
USA). A total of 16 dNPs were eluted from four distinct
spines (n=3–6 per spine). After 72 hours, eluted medium
from each sample was removed and 250 _L was added to
a 48-well plate containing ~7,500 human neonatal dermal fibroblasts (PCS-201-010, ATCC, Manassas, VA, USA)
in triplicate per sample. Control wells containing fresh
medium were also cultured (n=3). After 48 hours, a metabolic assay (DAL1100, Thermo Fisher) was performed to
assess the metabolic activity of eluted dNP samples medium versus control medium and determine if cytotoxic
residuals were present.

Normalized absorbance =

A – A0

Amax A0

(1)

Injectability of solubilized dNP matrix
To test the ability of the solubilized dNPs to be injected
and still form a gel, the samples were ejected through
a 30 gauge needle using a maximum force of <200 N,
which is the maximum applied force for injection by
hand [55]. After injection, the ability to thermally gel
was tested by incubating for 45 minutes at 37°C.
Microstructure
Decellularized, solubilized and re-gelled, solubilized injected and re-gelled, and fresh NP samples were each
prepared for scanning electron microscopy. The samples
were fixed in 4% PFA for 30 minutes, washed 3 × 15
minutes in 1× PBS, and then subjected to serial ethanol
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dehydration (30%, 50%, 70%, 85%, 90%, 95%, and
100%) over the course of 2 hours. After dehydration,
samples were dried using serial solutions of hexamethyldisilazane (25%, 50%, 75%, and 100%) over the course
of 2 hours. The samples were then left to dry overnight
in a fume hood in hexamethyldisilazane. High-resolution
scanning electron microscopy (SEM) was performed using a Nova NanoSEM (FEI, Hillsboro, OR, USA). Images
were acquired at magnifications ranging from 5,000× to
80,000×. ImageJ [56,57] was used to quantify fiber diameter at 20,000× and assess maintenance of structure
in decellularized, solubilized and re-gelled, solubilized injected and re-gelled, and fresh NP samples. A minimum
of five images per group were quantified, and a minimum
of 175 collagen fibers per image were measured.
NP cell-seeded constructs
Human nucleus pulposus cells (#4800, ScienCell Research Laboratories, Carlsbad, CA, USA) were cultured
and passaged in complete medium containing 1% penicillin-streptomycin, 10% fetal bovine serum, and 1% nucleus pulposus cell growth supplement (#4801, ScienCell
Research Laboratories) at 37°C and in normoxic conditions. Nucleus pulposus cells from passage 1 to 3 were
gently lifted using trypsin-EDTA (25200056, Thermo
Fisher) and mixed with solubilized dNP samples. Solubilized dNPs and cell mixtures were pipetted onto parafilm
in 30 μL droplets (40,000 cells per gel) and incubated
for 45 minutes at 37°C to allow for thermal gelation. After gelation, samples were placed in a 48-well plate and
immersed in 200 μL of complete medium. Two batches
of dNPs were cultured for 1, 7, or 21 days under hypoxic
conditions of 3.5% oxygen and 5% carbon dioxide to
mimic conditions present in in vivo nucleus pulposus
(n=6 per time point per batch).
Viability, sGAG content, and collagen content were determined at each time point. A standard live-dead assay using ethidium homodimer and calcein AM (L3224,
Thermo Fisher) was performed at days 1, 7, and 21 to determine cell viability in gels. After staining, confocal imaging was used to image intact gels (LSM 710, Zeiss Microimaging Inc.). A minimum of three 10× images were
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taken for each gel and quantified using Zeiss ZEN ImageAnalysis software (Zeiss Microimaging Inc.). Z-stack
images were also acquired to assess cell morphology in
gels. Sulfated glycosaminoglycan and collagen content
were analyzed using the methods listed in the DNA Removal and sGAG Maintenance section.
Statistics
Paired students t tests were performed to assess differences between dNPs and fresh NP controls (p<.05) for
the sGAG quantification, DNA content, collagen content,
metabolic activity assessment of cytotoxic residuals, and
SEM fiber diameters. In addition, an analysis of variance
with Tukey pairwise comparison was used to determine
differences in viability, sGAG content, and DNA content
between time points and batches in the nucleus pulposus cell-seeded construct experiment.
Results
DNA, sGAG, and collagen content
The results indicate that it was possible to create a gentle
decellularization procedure for porcine nucleus pulposus.
Over 96% of DNA content was removed in dNPs from cervical, thoracic, and lumbar segments (Fig. 3, Left). In addition, sGAG preservation was 44.5%, 21.9%, and 50.8%
for dNPs from cervical, thoracic, and lumbar segments,
respectively, as shown in Fig. 3, Middle. Because of the
low sGAG preservation in the thoracic discs, all following studies exclusively used cervical and lumbar discs for
processing and testing. The total collagen content was
maintained after decellularization, with dNP samples exhibiting a total collagen content of 18.6 μg of collagen per
milligram wet weight and control NP samples exhibiting
16.12 μg/mg (Fig. 3, Right). There was no significant difference between the two groups.
Cell removal and maintenance of CSPGs
Confocal imaging revealed faint DAPI staining in the majority of dNPs, with some containing no areas with any
DAPI staining. After decellularization, CSPGs were well

Fig. 3. DNA content was significantly removed in decellularized nuclei pulposi (dNPs) versus fresh nucleus pulposus (NP) controls, with
greater than 96% DNA being removed in all samples (Left) (p<.05). Sulfated glycosaminoglycans were well maintained (>45%) in the cervical and lumbar nuclei pulposi (Middle) (p<.05). Concentrations of soluble, insoluble, and total collagen were not significantly different
between the control NP and dNP samples (Right). Data (n=6) represent the mean±standard error.
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Fig. 4. Cell nuclei were removed (DAPI, left panels, blue) and chondroitin sulfate proteoglycans (CSPGs, right panels, red) were maintained
after decellularization of nuclei pulposi (Bottom) compared with fresh nuclei pulposi controls (Top).

preserved throughout the matrix. Fig. 4 is a representative image of a control nucleus pulposus (Top) and a
dNP (Bottom). No differences were observed between
the spine segments (cervical and lumbar); however, it
was not possible to quantify staining because of high
variability in cell density in different areas of the nucleus pulposus.
Cytotoxicity
The metabolic activity of human neonatal dermal fibroblasts with eluted dNP sample medium was not significantly lower than the control medium for any of the
samples tested. Across all samples tested, the average difference in metabolic activity compared with the control
medium was 1.11% ±2.1 standard error. This indicates
that there are no cytotoxic residuals remaining from the
decellularization process that impact cell function.
Creation of an injectable dNP matrix
The optimal parameters for the creation of a robust injectable dNP matrix were achieved by solubilizing minced
dNPs at 20 mg/mL in 1 mg/mL pepsin in 3% acetic acid,
homogenizing for 3 × 30 seconds, and stirring at room
temperature for 32 hours before neutralization and

buffering (Fig. 5). These gels could be manually manipulated and did not break apart when submerged in 1×
PBS for up to 7 days.
Gelation kinetics
Stabilization of absorbance of all four batches of dNP
samples occurred by ~40 minutes, indicating near complete gelation. A slope of 0 was observed in all samples
by 60 minutes, indicating complete gelation. Type I collagen controls (354236, Corning, Corning, NY, USA) exhibited complete gelation in 20 minutes.
Injectability of solubilized dNP matrix
The solubilized dNP samples were easily injected through
a 30 gauge syringe with minimal manual pressure. No
macroscopic disruption of the matrix was observed, and
they were able to form a smooth gel surface. Samples
gelled in ~40 minutes, similar to non-injected solubilized dNP controls. SEM was used to assess any changes
in microstructure.
Microstructure preservation
SEM revealed excellent preservation of microstructure
after decellularization, and solubilization and re-gelation

I n j e c ta b l e m at r i x f o r n u c l e u s p u l p o s u s t i s s u e e n g i n e e r i n g
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Fig. 5. Pictorial illustration of the digest and re-gelation process of the decellularized nuclei pulposi, from post-lyophilization (A), to fine
chop (B), to homogenization (C), and to post-gelation (D).

of NP samples (Fig. 6A, B, and C). The collagen fibrils
were intact and not substantially disrupted. Furthermore,
no cellular debris was apparent in dNPs. Although fiber
diameter was significantly increased after decellularization compared with controls, and significantly decreased
after solubilization compared with controls, both diameters were within 10% of the control NP fiber diameter
(Fig. 6D). The microstructure was also assessed after injection through a fine gauge needle and regelation of the
dNPs. There was no significant difference in fiber diameter of solubilized dNPs that were gelled without injection compared with those that were solubilized, injected,
and then gelled.
NP cell-seeded constructs
Nucleus pulposus cells maintained excellent viability (>89%) over the entire 21-day culture period, as
illustrated in Fig. 7, Left, with a significant increase
observed between day 1 and day 7, and no significant

differences observed between day 1 or day 7 and day 21.
In addition, by day 21, NP cells exhibited an elongated
morphology similar to that observed in native nucleus
pulposus cells (Fig. 7, Middle). There was an increase
in sGAG content over the 21-day culture period, which
was significant by day 21 (Fig. 7, Right). No significant
difference in DNA content was observed over the 21-day
culture period.
Discussion
This work demonstrates our ability to generate tissuespecific acellular matrices containing limited cell remnants and intact CSPGs for tissue engineering of the IVD.
These matrices have no detectable remaining cytotoxic
residuals and maintain fiber diameters similar to the native nucleus pulposus. Furthermore, the dNPs are able to
be modified to create an injectable formulation that can
support long-term culture of nucleus pulposus cells in vitro, suggesting it will be viable for in vivo studies.
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Fig. 6. Scanning electron micrographs at varying magnifications from 5,000× to 10,000× revealed similar fibrillar structure before (A)
and after (B) decellularization of the nuclei pulposi samples, as well as after solubilization (C). Average fiber diameters at 20,000× of decellularized nuclei pulposi (dNPs) and solubilized dNPs were within 10% of the fresh nuclei pulposi controls (D).

An optimized decellularization process for nucleus
pulposus needs to balance the removal of cells with the
maintenance of sGAGs. The sGAGs are essential in maintaining the osmotic pressure of the nucleus pulposus [8],
and they have the potential to play a role in driving cell
phenotype [45–47,50,58] and preventing innervation
[59–62]. The gentle decellularization protocol used in our
laboratory for nerve [39,43,63] and lung tissue [38] was
adapted for use in the nucleus pulposus by shortening the
duration of wash cycles substantially. The use of amphoteric and anionic detergents in short cyclic intervals enabled the preservation of nucleus pulposus microstructure, while also maintaining 45% to 51% of sGAGs and
removing >96% of DNA, similar to the methods previously developed by Mercuri et al. [44]. In addition, there
were no detectable cytotoxic residuals after processing,
as demonstrated by the elution study.

Preservation of sGAGs is an indirect indicator of preservation of CSPGs. In addition, our confocal results indicate preservation of CSPGs after decellularization. CSPGs
are known to be potent neurite inhibitors [11,12,60,64].
By maintaining CSPG presence in the matrix, this has the
potential to prevent nerve growth into the nucleus pulposus. Innervation of the nucleus pulposus has been demonstrated in patients with low back pain [13,14]. The ability of these solubilized dNP matrices to prevent nerve
growth in vitro and in vivo is currently being explored.
One of the major outputs of this work is the creation
of an in situ gelling decellularized nucleus pulposus. The
location of the nucleus pulposus inside the anulus fibrosus makes it difficult to access without damaging the anulus. Injectable in situ gelling matrices are the most viable therapeutic option to prevent damage to the anulus
fibrosus and future disc degeneration. Substantial work

Fig. 7. Viability of nucleus pulposus cell-seeded gels was high throughout the culture period (>89%) (Left). Nucleus pulposus cells were
well spread and displayed morphology similar to cells in native tissue by day 21 (Middle) (calcein staining). Sulfated glycosaminoglycan
content was significantly increased by day 21 (Right) (p<.05). Data (n=6 per time point per batch) represent the mean±standard error.
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has been performed in other tissue types to create injectable in situ gelling decellularized matrices [37,51,54],
but no work exists in the IVD. To date, the only injectable
decellularized nucleus pulposus was developed by IllienJünger et al. [47]. However, this matrix was created by
grinding the tissue to create small particles that were injected through a 25 gauge needle. This approach does not
enable in situ gelation and formation of a material able
to bear loads, and can potentially damage the anulus fibrosus. Ideally, a finer gauge needle would be used. Our
work demonstrates the creation of an in situ gelling decellularized nucleus pulposus that has the ability to act
as a cell carrier and be injected through a very fine needle (30 gauge) and still form a stable gel.
Matrix architecture and composition [65] can drive
cell fate. Specifically, recent work has demonstrated
that nucleus pulposus tissue alone has the potential to
drive stem cells toward an NP phenotype [66,67]. This is
likely due to the native microstructure as well as composition. Analysis via SEM revealed fiber diameters of dNP
samples and injectable dNP samples were within 10%
of fresh NP control samples. Furthermore, collagen and
sGAG in the NP extracellular matrix were maintained
during decellularization. Nucleus pulposus cell-seeded
gels cultured over 21 days demonstrated high viability,
NP-like morphology, and significantly increasing sGAG
content over time, indicating an appropriate matrix environment. These data support the conclusion that the
gel fiber morphology and composition of the samples are
maintained during decellularization and solubilization,
and have the potential to be ideal matrices for tissue engineering of the nucleus pulposus. Future work will explore the ability of the injectable dNPs created herein to
drive both stem cells and induce pluripotent stem cells
toward a nucleus pulposus cell phenotype.
Conclusions
In conclusion, we have created an acellular injectable
tissue-specific matrix that is well tolerated in vitro by
nucleus pulposus cells. This new matrix has the potential to be used for regenerative tissue engineering of the
nucleus pulposus to restore disc height and prevent unwanted painful innervation.
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